Video
Dr. Alexander Kretschmer explains how the ExoDx Prostate test works
Author(s):
Video Player is loading.
Dr. Alexander Kretschmer, MD, discusses the clinical interpretation and value of the ExoDx Prostate test (EPI test). The non-invasive, urine-based genomic test is a risk assessment tool that helps physicians and patients determine whether a prostate biopsy is necessary when PSA screening provides an ambiguous result.
Kretschmer is an assistant professor of Urology at Ludwig-Maximilians-University Munich.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans
The Current Landscape of ADT in Prostate Cancer
Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Post-RP incontinence: Low procedure rates examined
Data link incontinence severity to post-radical prostatectomy care
Related Content
